New Directions for Half-Life Extension of Protein Therapeutics: The Rise of Antibody Fc Domains and Fragments

Publisher： Bentham Science Publishers

E-ISSN： 1873-4316|17|15|1348-1352

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.17, Iss.15, 2016-12, pp. : 1348-1352

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Telaprevir in HIV/HCV-coinfected patients: a new standard with a short half-life

By Ingiliz Patrick  

Future Virology, Vol. 8, Iss. 8, 2013-08 ,pp. : 735-743

Future Medicine

Access to resources Recommend Favorite

Computation-Based Design and Engineering of Protein and Antibody Therapeutics

By  

Drug Design Reviews - Online, Vol. 2, Iss. 6, 2005-09 ,pp. : 419-425

Bentham Science Publishers

Access to resources Recommend Favorite

Discovery of Novel Candidate Therapeutics and Diagnostics Based on Engineered Human Antibody Domains

By  

Current Drug Discovery Technologies, Vol. 11, Iss. 1, 2014-03 ,pp. : 28-40

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Pharmacokinetics of Lornoxicam: A Short Half-life Oxicam

By Skjodt N.M.  

Clinical Pharmacokinetics, Vol. 34, Iss. 6, 1998-06 ,pp. : 421-428

Adis International

Access to resources Recommend Favorite

Protein Engineering: A New Frontier for Biological Therapeutics

By  

Current Drug Metabolism, Vol. 15, Iss. 7, 2014-01 ,pp. : 743-756

Bentham Science Publishers

Access to resources Recommend Favorite